Patents Issued in May 24, 2016
  • 6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD
    Patent number: 9345713
    Abstract: The present invention provides a method of treating acute heart failure by administering a compound of the formula: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: May 24, 2016
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Jason W. Brown, Melinda Davis, Anthony Ivetac, Benjamin Jones, Andre A. Kiryanov, Jon Kuehler, Marion Lanier, Joanne Miura, Sean Murphy, Xiaolun Wang
  • Method of treating middle ear infections
    Patent number: 9345714
    Abstract: Aqueous suspension formulations containing dexamethasone and ciprofloxacin are disclosed for the treatment of middle ear infections in human patients having an open tympanic membrane.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: May 24, 2016
    Assignee: Alcon Pharmaceuticals Ltd.
    Inventors: G. Michael Wall, Peter J. Conroy
  • Methods of treating diabetes or obesity using bile acids, bile salts, and mimics thereof
    Patent number: 9345715
    Abstract: Provided herein are methods and compositions for treating metabolic diseases and conditions associated with metabolic diseases.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: May 24, 2016
    Assignee: SATIOGEN PHARMACEUTICALS, INC.
    Inventors: Andrew A. Young, Bronislava Gedulin, Howard E. Greene
  • Protein free surfactant composition for pulmonary diseases and a process for preparing the same
    Patent number: 9345716
    Abstract: A protein free surfactant composition comprising dipalmitoylphosphatidyl choline (DPPC) and eugenol having a ratio in the range of 10:5 to 4:2 with >99% airway patency in the presence of albumin, for treating acid lung injury, adult respiratory distress syndrome and meconium aspiration syndrome.
    Type: Grant
    Filed: October 4, 2011
    Date of Patent: May 24, 2016
    Assignee: INDIAN INSTITUTE OF TECHNOLOGY, BOMBAY
    Inventors: Rinti Banerjee, Anubhav Kaviratna
  • Method for improving drug treatments in mammals
    Patent number: 9345717
    Abstract: An improved method for identifying the size, shape and duration of drug exposure necessary to improve drug treatment in a subject with a bacterial infection. In addition, an improved method for identification of new dosing strategies which optimize the probability of positive treatment outcomes in subjects using resistance inhibitory concentration (RIC), wherein the subject has a bacterial infection caused by a bacterium with a propensity for heteroresistance. Further, an improved method for decreasing the potential for on-therapy drug resistance by determining a patient's RIC prior to administration of fosfomycin treatment, wherein RIC is utilized to differentiate the parameter which is best related to the driver or index of fosfomycin efficacy for the resistant subpopulation present and the required inhibitory concentration of those mutants.
    Type: Grant
    Filed: September 25, 2014
    Date of Patent: May 24, 2016
    Assignee: Zavante Therapeutics, Inc.
    Inventors: Paul G. Ambrose, Evelyn Ellis-Grosse
  • Phospholipid ether analogs as cancer-targeting drug vehicles
    Patent number: 9345718
    Abstract: The present invention is directed to therapeutic compounds capable of targeting cancer cells and cancer stem cells. The present invention is further directed to compositions comprising these therapeutic compounds and methods of treating cancer comprising administering these therapeutic compounds.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: May 24, 2016
    Assignee: CELLECTAR BIOSCIENCES, INC.
    Inventors: Jamey P. Weichert, Anatoly Pinchuk, Kevin Kozak, Marc Longino, Joseph Grudzinski, Benjamin Titz, Chorom Pak, Nathan Stehle
  • Fused pyrimidine derivatives for inhibition of tyrosine kinase activity
    Patent number: 9345719
    Abstract: The present invention relates to a novel fused pyrimidine derivative having an inhibitory activity for tyrosine kinases, and a pharmaceutical composition for preventing or treating cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases comprising same as an active ingredient.
    Type: Grant
    Filed: October 23, 2014
    Date of Patent: May 24, 2016
    Assignee: Hanmi Science Co., Ltd.
    Inventors: Mi Young Cha, Seok Jong Kang, Mi Ra Kim, Ju Yeon Lee, Ji Young Jeon, Myoung Gi Jo, Eun Joo Kwak, Kwang Ok Lee, Tae Hee Ha, Kwee Hyun Suh, Maeng Sup Kim
  • Composition and method for treating wounds
    Patent number: 9345720
    Abstract: Provided, among other things, is a method of treating a wound comprising: periodically applying to the wound over a course of days an effective amount of a water based formulation (comprising: 0.5 to 5 wt % of an emollient comprising silicone oil, 2 to 10 wt % of fatty acid, humectant(s), emulsifying agent(s), and polymer(s)), wherein the formulation is formulated as a spray, cream, lotion, milk or foam-former.
    Type: Grant
    Filed: August 5, 2011
    Date of Patent: May 24, 2016
    Assignee: Exeltis USA Dermatology, Inc.
    Inventors: Christopher N. Hensby, Mats Silvander
  • Use of lactulose in the treatment of autism
    Patent number: 9345721
    Abstract: A treatment for autism in which an effective amount of lactulose is administered in order to bind excess ammonia in the gastrointestinal tract, the bloodstream, and the nervous system in order to prevent or reverse ammonia poisoning caused by the administration of certain antibiotics. Lactulose molecules in the colon are fermented by certain bacteria. The fermentation process lowers the colonic pH, and ammonia, in the form of ammonium ions, is used by the bacteria for amino acid and protein synthesis. This lowers the serum ammonia levels and reduces neurotoxicity.
    Type: Grant
    Filed: November 22, 2013
    Date of Patent: May 24, 2016
    Assignee: Curemark, LLC
    Inventors: Joan M. Fallon, Richard Feltenstein
  • Pharmaceutical formulations for the treatment of alzheimer's disease
    Patent number: 9345722
    Abstract: The present invention relate to pharmaceutical formulations that include a CPHPC component and a delivery agent compound.
    Type: Grant
    Filed: July 24, 2007
    Date of Patent: May 24, 2016
    Assignee: EMISPHERE TECHNOLOGIES, INC.
    Inventors: Ihor Shevchuk, Steven Dinh
  • Rapid formation of chitosan sponges using guanosine 5?-diphosphate: injectable scaffolds for tissue regeneration and drug delivery
    Patent number: 9345723
    Abstract: It is disclosed Guanosine 5?-Diphosphate (GDP) crosslinked chitosan sponge or gelling composition which is used as a scaffold for tissue regeneration applications such as neural, cardiac, cartilage and bone regeneration. In addition, the sponge acts as a drug delivery system to provide local controlled drug release, such as delivering anti-cancer drugs locally at the tumor site.
    Type: Grant
    Filed: September 4, 2013
    Date of Patent: May 24, 2016
    Inventors: Mina Mekhail, Guillermina Almazan, Maryam Tabrizian
  • Sodium thiosulfate-containing pharmaceutical compositions
    Patent number: 9345724
    Abstract: Provided herein are pharmaceutically acceptable sodium thiosulfate and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-purgeable organic carbon in a sodium thiosulfate-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium thiosulfate. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium thiosulfate.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: May 24, 2016
    Assignee: Hope Medical Enterprises, Inc.
    Inventors: Craig Sherman, Catherine Marie Smith, Kevin Robert Wirtz, Erich Schulze
  • Pharmaceutical formulations of gallium salts
    Patent number: 9345725
    Abstract: The present invention relates to pharmaceutical formulations containing a pharmaceutically acceptable gallium salt (such as gallium nitrate), a delivery agent, and optionally, one or more chemotherapeutic agents and/or adjunctive chemotherapeutic agents.
    Type: Grant
    Filed: December 29, 2005
    Date of Patent: May 24, 2016
    Assignee: EMISPHERE TECHNOLOGIES, INC.
    Inventors: Lewis Bender, Bavani Shankar, Catherina O'Shaughnessy
  • CD117+ cells and uses thereof
    Patent number: 9345726
    Abstract: The present invention provides compositions comprising CD117+ cells and methods for using the same in allograft. In some aspects of the invention, methods are provided for prolonging allograft survival in a subject by administering CD117+ cells.
    Type: Grant
    Filed: September 7, 2010
    Date of Patent: May 24, 2016
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Todd J. Grazia, Martin R. Zamora, Robert J. Plenter
  • Nutritional compositions containing a peptide component and uses thereof
    Patent number: 9345727
    Abstract: The present disclosure relates to nutritional compositions including a protein equivalent source including a peptide component comprising selected peptides from Tables 1 and 2 disclosed herein. The protein equivalent source may further include intact protein, hydrolyzed protein, including partially hydrolyzed protein, or combinations thereof. The disclosure further relates to methods of reducing the incidence of autoimmune disease and/or diabetes mellitus by providing said nutritional compositions to a target subject, which includes a pediatric subject.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: May 24, 2016
    Assignee: Mead Johnson Nutrition Company
    Inventors: Dirk Hondmann, Eric A. F. van Tol, Gabriele Gross, Marieke H. Schoemaker, Teartse Tim Lambers
  • Non-replicating probiotic micro-organisms protect children against gastrointestinal infections
    Patent number: 9345728
    Abstract: The present invention relates to non-replicating probiotic micro-organisms and their health benefits. In particular, the present invention provides a means to help parents to protect their children from gastro-intestinal infections, in particular diarrhea. One embodiment of the present invention relates to a composition comprising non-replicating probiotic micro-organisms for use in the prevention or treatment of gastrointestinal infections in children.
    Type: Grant
    Filed: November 9, 2011
    Date of Patent: May 24, 2016
    Assignee: Nestec S.A.
    Inventors: Valerie Petit, Clara Lucia Garcia-Rodenas, Monique Julita, Annick Mercenier, Guenolee Prioult, Sophie Nutten
  • Method for treating or preventing heart diseases
    Patent number: 9345729
    Abstract: This invention discloses a method for treating or preventing heart diseases by using a probiotic composition. The method for treating or preventing heart diseases comprises administering to a subject an effective amount of a probiotic composition to prevent the myocardial cells from myocardial hypertrophy, fibrosis and apoptosis, wherein the probiotic composition comprising Lactobacillus rhamnosus LCR177 (BCRC910473), Pediococcus acidilactici PA318 (BCRC910474) and Bifidobacterium adolescentis (BCRC14609).
    Type: Grant
    Filed: November 19, 2014
    Date of Patent: May 24, 2016
    Assignee: NEW BELLUS ENTERPRISES CO., LTD.
    Inventors: Cheng-Chih Tsai, Chih-Yang Huang, Hsueh-Fang Wang, Chun-Hua Chen, Chun-Chih Huang
  • Methods of treating impaired glucose metabolism via administration of algal biomass
    Patent number: 9345730
    Abstract: The invention is directed to methods of using Chlorella protothecoides microalgal biomass in the treatment of individuals having impaired glucose metabolism. In some cases, the patient has impaired fasting glucose, impaired glucose tolerance, or diabetes. In some methods, algal biomass is used to reduce blood glucose and/or body fat in a subject, or to increase the relative abundance of beneficial gut microflora in a subject. In preferred embodiments, the biomass is derived from Chlorella protothecoides cultures grown heterotrophically in which the algal cells comprise at least 15% algal oil by dry weight.
    Type: Grant
    Filed: April 30, 2014
    Date of Patent: May 24, 2016
    Assignees: SOLAZYME, INC., UNIVERSITY OF MANITOBA
    Inventors: David Brinkmann, Anthony G. Day, Peter J. H. Jones, Scott Harding
  • Herbal extract as sensitivity enhancer toward insulin and antidiabetes
    Patent number: 9345731
    Abstract: A herbal extract composition from Lythraceae and Lauraceae family plants and its usage as insulin resistance reducer, syndrome X normalization, pre-diabetes and type 2 diabetes treatments, particularly as activator in insulin signal pathway, as modulator in glucose transport system, as modulator in adiponectin secretion, and as suppressor in insulin resistance. Representative from Lythraceae family has been selected Lagerstroemia speciosa, and representative from Lauraceae family has been selected Cinnamomum burmannii. Such herbal extract composition work synergistically to strengthen pharmacological effect produced by each extract if they act alone.
    Type: Grant
    Filed: August 4, 2009
    Date of Patent: May 24, 2016
    Assignee: PT. DEXA MEDICA
    Inventors: Raymond R. Tjandrawinata, James M. Sinambela, Olivia Mayasari, Deasy Diah Dwi R. W., Melissa Puspasari
  • Agents derived from Holoptelea integrifolia and their compositions for the control of metabolic syndrome and associated diseases
    Patent number: 9345732
    Abstract: The invention discloses phytochemical agents derived from Holoptelea integrifolia and novel composition(s) comprising at least one component selected from the extract(s), fraction(s) and active compound(s) for the protection and alleviation of Metabolic Syndrome, insulin resistance, endothelial dysfunction, chronic kidney disease, atherosclerosis, diabetes and other disease conditions associated with metabolic syndrome. The invention also discloses the amelioration of certain biomarker molecules such as Peroxisome proliferator-activated receptor gamma (PPAR-?), Adipose Differentiation Related Protein (ADRP), CD36, Adipocyte Fatty-acid-Binding Protein (aP2/FABP-4/A-FABP), beta-3 Adrenergic Receptor (?3AR), Leptin, Perilipin and Adiponectin by using the phytochemical components derived from Holoptelea integrifolia.
    Type: Grant
    Filed: November 19, 2009
    Date of Patent: May 24, 2016
    Assignee: Laila Nutraceuticals
    Inventors: Ganga Raju Gokaraju, Rama Raju Gokaraju, Venkata Kanaka Ranga Raju Gokaraju, Trimurtulu Golakoti, Kiran Bhupathiraju, Venkateswara Rao Chirravuri, Sivaramakrishna Chillara
  • Supplement composition for supporting telomere maintenance and protection and method of use
    Patent number: 9345733
    Abstract: A supplement composition for supporting telomere maintenance and protection, including effective amounts of extract of silybum marianum; N-acetylcysteine; Resveratrol; Extract of Panax ginseng; Extract of Ginkgo biloba; Puerarin; and L-arginine. Further disclosed is a method for supporting telomere maintenance and protection, comprising orally administering a supplement composition to a person one or twice daily, said supplement composition comprising in one dosage: from about 100 mg to about 300 mg of extract of silybum marianum, from about 400 mg to about 600 mg of N-acetylcysteine, from about 40 mg to about 60 mg of trans-resveratrol, from about 80 mg to about 120 mg of extract of Panax ginseng, from about 40 mg to about 60 mg of extract of ginkgo biloba, and from about 80 mg to about 120 mg of puerarin, and from about 400 mg to about 600 mg of L-arginine.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: May 24, 2016
    Assignee: CELLHEALTH TECHNOLOGIES LTD.
    Inventors: Vincent C. Giampapa, David B. Cross
  • extract, method for preparing extract and method for treating chronic myeloid leukemia
    Patent number: 9345734
    Abstract: An Achillea fragrantissima extract for treating chronic myeloid leukemia cells is made by the following steps: washing a mass of Achillea fragrantissima leaves and powdering the dried leaves. The leaves are dried over seven days and a kilo of the powder is extracted three times with methanol. The resulting material is concentrated and redissolved in water to form a concentration of 0.5 mg/mL and centrifuged to remove any undissolved material. The final Achillea fragrantissima extract may then be used to cause morphological changes in CML cells and treat humans with chronic myeloid leukemia.
    Type: Grant
    Filed: April 23, 2013
    Date of Patent: May 24, 2016
    Assignee: King Saud University
    Inventors: Asma Majed Alenad, Nabila Abdul-Aziz Al-Jaber
  • Fenugreek seed extract to lower blood cholesterol
    Patent number: 9345735
    Abstract: A method of lowering blood cholesterol in a non-diabetic patient by at least 30% is described. The method involves orally administering for 30 consecutive days a fenugreek seed extract composition. Various methods of preparation and various formulations are described. Physiologically effective pharmaceutical compositions and beverages containing fenugreek seed extracts and other active components are also disclosed.
    Type: Grant
    Filed: November 14, 2012
    Date of Patent: May 24, 2016
    Inventors: S. George Aburdeineh, Hikmat George Aburdeineh
  • Topical treatment of radiation dermatitis using hamelia patens
    Patent number: 9345736
    Abstract: Topical compositions are provided useful for treating radiation dermatitis. The compositions comprise an extract of the plant Hamelia patens and are applied topically to skin having radiation dermatitis to relieve symptoms thereof.
    Type: Grant
    Filed: March 16, 2013
    Date of Patent: May 24, 2016
    Assignee: BERRY PHARMACEUTICALS, L.L.C.
    Inventor: Don Wayne Berry
  • Topical treatment of keratotic lesions using hamelia patens
    Patent number: 9345737
    Abstract: Topical compositions are provided useful for treating keratosis. The compositions comprise an extract of the plant Hamelia patens and are applied topically to skin having radiation dermatitis to relieve symptoms thereof.
    Type: Grant
    Filed: February 12, 2014
    Date of Patent: May 24, 2016
    Assignee: BERRY PHARMACEUTICALS, L.L.C.
    Inventor: Don Wayne Berry
  • Methods for the prevention or treatment of no-reflow following ischemia/reperfusion injury
    Patent number: 9345738
    Abstract: The invention provides methods of preventing or treating cardiac ischemia-reperfusion injury in a mammalian subject. The methods provide administering aromatic-cationic peptides in effective amounts to prevent or treat an anatomic zone of no re-flow in mammalian subjects. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: May 24, 2016
    Assignees: Stealth BioTherapeutics Corp., Heart Institute Good Samaritan Hospital
    Inventors: D. Travis Wilson, Kenneth Borow, Robert A. Kloner, Sharon Hale
  • Methods and compositions for the treatment of proteinuric diseases
    Patent number: 9345739
    Abstract: The present invention is directed to methods of treating proteinuric diseases by the administration of av?3 integrin inhibitors.
    Type: Grant
    Filed: November 7, 2008
    Date of Patent: May 24, 2016
    Assignee: The General Hospital Corporation
    Inventor: Jochen Reiser
  • IAP antagonists
    Patent number: 9345740
    Abstract: There are disclosed compounds that modulate the activity of inhibitors of apoptosis (IAPs), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.
    Type: Grant
    Filed: July 10, 2013
    Date of Patent: May 24, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventor: Kyoung S. Kim
  • Nutritional composition containing a peptide component with adiponectin simulating properties and uses thereof
    Patent number: 9345741
    Abstract: The present disclosure relates to nutritional compositions including a protein equivalent source that includes a peptide component comprising selected peptides. The protein equivalent source may further include intact protein, hydrolyzed protein, including partially hydrolyzed protein, or combinations thereof. The disclosure further relates to methods of promoting healthy body weight in a target subject by stimulating adiponectin levels by providing the nutritional compositions disclosed herein to a target subject, which includes a pediatric subject.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: May 24, 2016
    Assignee: Mead Johnson Nutrition Company
    Inventors: Dirk Hondmann, Eric A. F. Van Tol, Gabriele Gross, Marieke H. Schoemaker, Teartse Tim Lambers, Tania Ramacho, Manuela Elsen, Jürgen Eckel
  • Aminostatin derivatives for the treatment of arthrosis
    Patent number: 9345742
    Abstract: The present invention relates to compounds of the formula (I) and in particular medicaments comprising at least one compound of the formula (I) for use in the treatment and/or prophylaxis of physiological and/or pathophysiological states in the triggering of which cathepsin D is involved, in particular for use in the treatment and/or prophylaxis of arthrosis, traumatic cartilage injuries, arthritis, pain, allodynia or hyperalgesia.
    Type: Grant
    Filed: January 9, 2012
    Date of Patent: May 24, 2016
    Assignee: MERCK PATENT GMBH
    Inventors: Markus Klein, Christos Tsaklakidis, Hans Guehring, Brigitta Leuthner
  • Agent for promoting proliferation of bifidobacteria
    Patent number: 9345743
    Abstract: A peptide dimer comprising a peptide consisting of the amino acid sequence of SEQ ID NO: 1 and a peptide consisting of any one of the amino acid sequences of SEQ ID NOS: 2 to 4, wherein the peptide consisting of the amino acid sequence of SEQ ID NO: 1 and the peptide consisting of any one of the amino acid sequences of SEQ ID NOS: 2 to 4 are bound through a disulfide bond between a cysteine residue of each peptide is used as an active ingredient of an agent for promoting proliferation of one or more bacterium selected from the group consisting of Bifidobacterium infantis and Bifidobacterium breve.
    Type: Grant
    Filed: August 24, 2012
    Date of Patent: May 24, 2016
    Assignee: MORINAGA MILK INDUSTRY CO., LTD.
    Inventors: Hirotsugu Oda, Koji Yamauchi, Takumi Sato, Kanetada Shimizu
  • Peptide-based collagen modulators for wound healing and tissue repair
    Patent number: 9345744
    Abstract: Provided are peptides that can inhibit collagen synthesis, processing and/or secretion from scar forming cells or fibroblasts. Also provided are methods for using the peptides to produce an anti-fibrotic, anti-scarring, anti-inflammatory, and/or pro-regenerative effect, e.g., on an injured or diseased tissue.
    Type: Grant
    Filed: April 25, 2013
    Date of Patent: May 24, 2016
    Assignees: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT, UNIVERSITY OF SOUTH CAROLINA
    Inventors: Robert G. Gourdie, Edie C. Goldsmith, L. Jane Jourdan, Joshua Matthew Rhett, Michael J. Yost
  • Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
    Patent number: 9345745
    Abstract: The described invention provides methods for treating an inflammatory brain disease, disorder or condition and for treating a traumatic brain injury having an inflammatory component in a subject in need thereof using isolated erythropoietin (EPO)-derived oligopeptides.
    Type: Grant
    Filed: March 28, 2011
    Date of Patent: May 24, 2016
    Inventors: Bo Wang, Rui Rong Yuan, Wei Lu, Peter C. Dowling
  • Immunogenic heat stable enterotoxin
    Patent number: 9345746
    Abstract: The present invention relates to methods and compositions for the treatment and prevention of diarrhea and diarrheal related diseases and disorders in both animals and humans. In some embodiments, the invention relates to the treatment of said diarrhea and diarrheal related diseases and disorders with a vaccine. In still further embodiments, the invention relates to the treatment of constipation using the disclosed methods and compositions.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: May 24, 2016
    Assignee: BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY
    Inventor: A. Mahdi Saeed
  • Composition and use thereof in the treatment of anal rhagades
    Patent number: 9345747
    Abstract: The present invention relates to a composition comprising at least one protein extract of hibiscus and/or at least one beta glucan or a salt thereof. Furthermore, the present invention relates to the use of said composition for the treatment of anal rhagades.
    Type: Grant
    Filed: January 30, 2012
    Date of Patent: May 24, 2016
    Assignee: THD
    Inventors: Filippo Bastia, Maurizio Saccomanno
  • Anti-SSX-2 T cell receptors and related materials and methods of use
    Patent number: 9345748
    Abstract: The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for synovial sarcoma X Breakpoint (SSX)-2. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are further provided by the invention.
    Type: Grant
    Filed: September 14, 2011
    Date of Patent: May 24, 2016
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Richard A. Morgan, Nachimuthu Chinnasamy, Dhanalakshmi Chinnasamy, Steven A. Rosenberg
  • Method of treating intraoccular tissue pathologies with nerve growth factor
    Patent number: 9345749
    Abstract: Nerve Growth Factor (NGF), in the form of a preparation to be administered over ocular surface, is suggested as being suitable for therapy and/or prophylaxis of intraocular tissue pathologies, with particular reference to sclera, ciliary body, crystalline lens, retina, optic nerve, vitreous body and choroidea affections. When administered in the form of external ophthalmic preparation, for example as collyrium or ointment, NGF is capable to go through ocular tissues and it has been found out that it shows a therapeutic activity not only against retina and optic nerve pathologies but also against affections involving the above reported internal structures of the eye.
    Type: Grant
    Filed: February 14, 2012
    Date of Patent: May 24, 2016
    Assignee: DOMPÉ FARMACEUTICI S.P.A.
    Inventor: Alessandro Lambiase
  • Long-acting formulations of insulin
    Patent number: 9345750
    Abstract: The application relates to an aqueous pharmaceutical formulation comprising 200-1000 U/mL [equimolar to 200-1000 IU human insulin] of insulin glargine.
    Type: Grant
    Filed: March 20, 2014
    Date of Patent: May 24, 2016
    Assignee: SANOFI
    Inventors: Reinhard Becker, Annke Hahn, Peter Boderke, Christiane Fuerst, Werner Mueller, Ulrich Werner
  • venom administration for cancer treatment
    Patent number: 9345751
    Abstract: A method for treating cancer using an intra-patient dose escalation procedure to deliver dosages of Crotalus durissus terrificus venom.
    Type: Grant
    Filed: December 30, 2014
    Date of Patent: May 24, 2016
    Assignee: Celtic Biotech Iowa, Inc.
    Inventor: Paul F. Reid
  • Therapeutic vegetable substances
    Patent number: 9345752
    Abstract: A product containing papain, bromelain or mixtures thereof is intended for use as a medicinal product at a dosage of at least 5000 mg administered for at least one day in a single dose. This dosage relates to papain powder having a titer of 3 U/mg and bromelain powder having a titer of 2 U/mg, and to a patient with a body weight of 55 kg. In the case of variations of the titer and/or of the patient's weight, the dosage must be varied in proportion to said variations.
    Type: Grant
    Filed: December 28, 2012
    Date of Patent: May 24, 2016
    Inventors: Giuseppe Carpignoli, Alberto Di Giovanni
  • Vaccine for alzheimer's disease
    Patent number: 9345753
    Abstract: Compositions and methods for prevention and treatment of Alzheimer's disease utilize a combination of amyloid-beta protein or a fragment thereof and a heat shock protein or a fragment thereof.
    Type: Grant
    Filed: January 15, 2009
    Date of Patent: May 24, 2016
    Assignees: YEDA RESEARCH AND DEVELOPMENT CO. LTD. AT THE WEIZMANN INSTITUTE OF SCIENCE, BEN-GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY
    Inventors: Alon Monsonego, Irun R. Cohen
  • Allogeneic tumor therapeutic agent, a vaccine using allogeneic tumor cells for the therapeutic treatment of tumor diseases, and a method for the making of such a vaccine, and transfected human tumor cells for use as a vaccine
    Patent number: 9345754
    Abstract: A vaccine on the basis of allogeneic tumor cells for the therapeutic treatment of defined tumor diseases, and a method for the making of such vaccine is disclosed. The tumor cells were previously transfected ex vivo with expression constructs encoding cytokines and co-stimulatory factors.
    Type: Grant
    Filed: November 9, 2009
    Date of Patent: May 24, 2016
    Assignee: Mologen AG
    Inventors: Tomislav Dobric, Burghardt Wittig, Manuel Schmidt
  • Composition and methods for treating melanoma
    Patent number: 9345755
    Abstract: The present invention encompasses novel peptides useful for preventing and treating cancer, particularly melanoma. Multiple sequences of interest are provided and these sequences have been incorporated into other peptides to obtain a series of peptides of about 30 amino acid residues in length wherein the properties of each combine to yield an effective cocktail for treating melanoma, which surpasses the use of single peptides as immunogens, as well as shorter peptides as immunogens.
    Type: Grant
    Filed: February 20, 2013
    Date of Patent: May 24, 2016
    Assignee: University of Virginia Patent Foundation
    Inventors: Craig L. Slingluff, Jr., Victor H. Engelhard
  • LPS vaccine
    Patent number: 9345756
    Abstract: A vaccine composition for birds comprising as an active ingredient a structure containing O-antigen derived from Gram-negative bacteria, provided that said structure does not contain a whole cell, and a process for preparing the same are provided. By using a structure containing O-antigen (e.g. lipopolysaccharide) derived from Gram-negative bacteria as an active ingredient in accordance with the present invention, alleviation of inoculation reaction and reduction in an amount of injection are attained as compared to the conventional whole-cells vaccine to thereby allow for the increase in the number of other antigens to be mixed therewith.
    Type: Grant
    Filed: February 19, 2013
    Date of Patent: May 24, 2016
    Assignee: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
    Inventors: Ryuichi Sakamoto, Masashi Sakaguchi
  • Chimeric protein vaccine against pneumonia caused by
    Patent number: 9345757
    Abstract: A vaccine comprising a chimeric protein set forth as SEQ ID NO: 1 containing immunogenic epitopes of conservative Streptococcus pneumoniae proteins PspA, Spr1895, PsaA, as well as flagellin components, connected via flexible links, wherein the flagellin components function as adjuvant.
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: May 24, 2016
    Assignee: EPITOPE LIMITED
    Inventors: Aleksandr Nikolaevich Suvorov, Ilya Vladimirovich Dukhovlinov, Anton Iosifovich Orlov, Evgenii Jakovlevich Baiguzin
  • Materials and methods for respiratory disease control in canines
    Patent number: 9345758
    Abstract: The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention.
    Type: Grant
    Filed: April 19, 2011
    Date of Patent: May 24, 2016
    Assignees: University of Florida Research Foundation, Inc., The United States of America as represented by The Secretary of The Department of Health and Human Services, Centers for Disease Control and Prevention, Cornell Research Foundation, Inc.
    Inventors: Patti C. Crawford, Paul J. Gibbs, Edward J. Dubovi, Ruben Omar Donis, Jacqueline Katz, Alexander I. Klimov, Nallakannu P. Lakshmanan, Melissa Anne Lum, Daniel Ghislena Emiel Goovaerts, Mark William Mellencamp, William L. Castleman, Nancy J. Cox
  • Bluetongue virus recombinant vaccines and uses thereof
    Patent number: 9345759
    Abstract: The present invention encompasses BTV vaccines or compositions. The vaccine or composition may be a vaccine or composition containing BTV antigens. The invention also encompasses recombinant vectors encoding and expressing BTV antigens, epitopes or immunogens which can be used to protect animals, such as ovines, bovines, or caprines, against BTV.
    Type: Grant
    Filed: March 11, 2011
    Date of Patent: May 24, 2016
    Assignee: MERIAL, INC.
    Inventors: Jean-Christophe Audonnet, Xuan Guo, Kevin Cox
  • IPNV-ISAV bivalent vaccine using a virus-like particle-based platform and methods of using the same
    Patent number: 9345760
    Abstract: The present invention provides bivalent oral vaccines against infectious pancreatic necrosis virus (IPNV) and infectious salmon anemia virus (ISAV). Yeast cells comprise an expression vector comprising (i) a polynucleotide sequence encoding a VP2 capsid protein of IPNV and (ii) a polynucleotide sequence encoding one or more antigenic epitopes of hemaglutinin of ISAV. The yeast cells express sub-viral particles (SVP) comprising a VP2 capsid protein of IPNV and one or more antigenic epitopes of hemaglutinin of ISAV. The yeast cells and SVP may be administered in an effective amount to increase the amount of antibodies against IPNV and ISAV in the fish, preferably Salmonidae. The yeast cells and SVP may be in the form of fish food for administering to the fish orally.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: May 24, 2016
    Assignee: Advanced Bionutrition Corporation
    Inventor: Arun K. Dhar
  • Methods and compositions for dosing of allergens
    Patent number: 9345761
    Abstract: The present invention comprises methods and compositions for immunotherapy. An aspect of the invention comprises administration of one or more allergens in compositions via oral and sublingual routes. Allergen compositions are administered in dosing intervals wherein the increase in the one or more allergens administered to the patient are provided in increasing volumes of a single concentration of at least one allergen.
    Type: Grant
    Filed: July 19, 2013
    Date of Patent: May 24, 2016
    Assignee: GREER LABORATORIES, INC.
    Inventor: Robert E. Esch
  • Stayed roller furler
    Patent number: 9345762
    Abstract: A wind powered craft carrying a generally vertical mast which is rotatable about its vertical axis, having a sail carried by the mast with its bottom edge attached in proximity to the bottom of the mast and extending to an attachment point in proximity to the top of the mast. A generally horseshoe-shaped member having an open end is and extending around said mast. The mast being rotatable within the horseshoe-shaped member. A bearing supported stationary member at the top of the mast is carried by the mast while allowing the mast to rotate. A support stay runs from the horseshoe-shaped member to the bearing supported member to support the horseshoe-shaped member. Additional stays are attached to the horseshoe-shaped member and splayed to attach to opposed sides of the hull of the watercraft. The sail is reefed around the mast through the open end of the horseshoe-shaped member.
    Type: Grant
    Filed: November 18, 2014
    Date of Patent: May 24, 2016
    Assignee: Hobie Cat Company
    Inventors: Philip James Dow, Gregory Scott Ketterman, James Taylor Czarnowski, Jason Christopher Kardas